JP2013503819A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503819A5
JP2013503819A5 JP2012526118A JP2012526118A JP2013503819A5 JP 2013503819 A5 JP2013503819 A5 JP 2013503819A5 JP 2012526118 A JP2012526118 A JP 2012526118A JP 2012526118 A JP2012526118 A JP 2012526118A JP 2013503819 A5 JP2013503819 A5 JP 2013503819A5
Authority
JP
Japan
Prior art keywords
independently
olr
compound according
compound
saturated aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012526118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503819A (ja
JP5778675B2 (ja
Filing date
Publication date
Priority claimed from GBGB0915196.0A external-priority patent/GB0915196D0/en
Application filed filed Critical
Publication of JP2013503819A publication Critical patent/JP2013503819A/ja
Publication of JP2013503819A5 publication Critical patent/JP2013503819A5/ja
Application granted granted Critical
Publication of JP5778675B2 publication Critical patent/JP5778675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012526118A 2009-09-01 2010-09-01 治療性アリール−アミド−アリール化合物およびその使用 Expired - Fee Related JP5778675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0915196.0 2009-09-01
GBGB0915196.0A GB0915196D0 (en) 2009-09-01 2009-09-01 Therapeutic compounds and their use
PCT/GB2010/001650 WO2011027106A1 (en) 2009-09-01 2010-09-01 Therapeutic aryl-am i do-aryl compounds and their use

Publications (3)

Publication Number Publication Date
JP2013503819A JP2013503819A (ja) 2013-02-04
JP2013503819A5 true JP2013503819A5 (cg-RX-API-DMAC7.html) 2013-08-22
JP5778675B2 JP5778675B2 (ja) 2015-09-16

Family

ID=41202973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012526118A Expired - Fee Related JP5778675B2 (ja) 2009-09-01 2010-09-01 治療性アリール−アミド−アリール化合物およびその使用

Country Status (15)

Country Link
US (2) US20120149737A1 (cg-RX-API-DMAC7.html)
EP (1) EP2473479A1 (cg-RX-API-DMAC7.html)
JP (1) JP5778675B2 (cg-RX-API-DMAC7.html)
CN (1) CN102639487A (cg-RX-API-DMAC7.html)
AU (1) AU2010291056B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004173A2 (cg-RX-API-DMAC7.html)
CA (1) CA2771097C (cg-RX-API-DMAC7.html)
GB (1) GB0915196D0 (cg-RX-API-DMAC7.html)
IL (1) IL218137A (cg-RX-API-DMAC7.html)
MX (1) MX2012002481A (cg-RX-API-DMAC7.html)
NZ (1) NZ598331A (cg-RX-API-DMAC7.html)
RU (1) RU2012108173A (cg-RX-API-DMAC7.html)
SG (1) SG178480A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011027106A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201287B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
CN102727475B (zh) * 2012-06-14 2014-05-07 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治老年痴呆药物中的应用
CN107207488B (zh) * 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
US20190112272A1 (en) * 2016-04-07 2019-04-18 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
CA3124039A1 (en) * 2018-12-19 2020-06-25 King's College London Immunotherapeutic methods and compositions
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
CA3128032A1 (en) 2019-01-29 2020-08-06 The Johns Hopkins University Small molecule neutral sphingomyelinase 2 (nsmase2) inhibitors
US12540121B2 (en) 2019-06-28 2026-02-03 Arizona Board Of Regents On Behalf Of Arizona State University Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260118C2 (de) 1972-12-08 1982-06-03 Bayer Ag, 5090 Leverkusen Penicilline sowie ihre Verwendung als Arzneimittel
EP0170105B1 (en) 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
JPS61233678A (ja) 1985-04-09 1986-10-17 Maruko Seiyaku Kk ベンジルピペラジン誘導体
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
US4808631A (en) 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
AU7317391A (en) 1990-02-14 1991-09-03 Chugai Seiyaku Kabushiki Kaisha Inhibitor of denatured ldl formation
FR2663850B1 (fr) 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5648385A (en) 1994-01-03 1997-07-15 Bristol-Myers Squibb Co. Retinoid-like compounds
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5559248A (en) 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
AU693682B2 (en) 1995-04-10 1998-07-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
WO2000001679A1 (en) 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor regulators
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
TW400614B (en) 1998-11-06 2000-08-01 United Microelectronics Corp The manufacture method of Shallow Trench Isolation(STI)
CN1225468C (zh) 2000-09-22 2005-11-02 全药工业株式会社 头孢烯化合物以及含有该化合物的esbl检测试剂
AU2002231098A1 (en) 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
KR100921173B1 (ko) * 2007-11-14 2009-10-13 (주)아모레퍼시픽 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물
BRPI1013392A2 (pt) 2009-03-31 2016-03-29 Renascience Co Ltd inibidor do inibidor-1 do ativador do plasminogênio
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2012058378A1 (en) 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses

Similar Documents

Publication Publication Date Title
CN104011034B (zh) 用于生产1-[2-(2,4-二甲基-苯基硫烷基)-苯基]-哌嗪的方法
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
DK2509940T3 (en) AMYLOID BINDING AGENTS
RU2013150811A (ru) Ингибиторы идо
JP2016512822A5 (cg-RX-API-DMAC7.html)
AU2018216954B2 (en) Piperazine derivatives for influenza virus inhibition
JP2014514286A5 (cg-RX-API-DMAC7.html)
JP2014043463A (ja) アルカノイルアミノベンズアミドアニリンhdacインヒビター化合物
RU2011126607A (ru) Нитратные производные цилостазола для лечения сосудистых заболеваний и нарушений обмена веществ
JP2011526594A5 (cg-RX-API-DMAC7.html)
JP2020527175A5 (cg-RX-API-DMAC7.html)
PT2420491E (pt) Compostos de piperidina 3,5-substituída como inibidores de renina
HRP20151336T1 (hr) Tetrahidroizokinolin-1-on derivat ili njegova sol
JP2013514974A5 (cg-RX-API-DMAC7.html)
CA2526506A1 (en) Inhibitors of papilloma virus
JP2010506910A5 (cg-RX-API-DMAC7.html)
CN113347979B (zh) 碳硼烷化合物、碳硼烷类似物及其使用方法
JP2002526522A5 (cg-RX-API-DMAC7.html)
JP2015515465A5 (cg-RX-API-DMAC7.html)
CN105622524A (zh) 截短侧耳素类衍生物及其应用
PL207487B1 (pl) Pochodna aminobenzofenonu o wzorze I, jej zastosowanie i kompozycja zawierająca ten związek
JP2013525473A5 (cg-RX-API-DMAC7.html)
AU2012320010B2 (en) Quinoline-, quinoxaline or benzothiazole based cysteinyl leukotriene antagonists (LTD4)
JP2022528271A5 (cg-RX-API-DMAC7.html)
CA3006541C (en) Compositions and methods for treating diseases and conditions